DrugPatentWatch Database Preview

Details for Patent: 9,187,405

« Back to Dashboard

Which drugs does patent 9,187,405 protect, and when does it expire?

Patent 9,187,405 protects GILENYA and is included in one NDA.

This patent has twenty-six patent family members in twelve countries.

Summary for Patent: 9,187,405

Title:	S1P receptor modulators for treating relasping-remitting multiple sclerosis
Abstract:	The present invention relates uses of an S1P receptor modulator such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e. g. a compound comprising a group of formula X ##STR00001## for the treatment or prevention of neo-angiogenesis associated with a demyelinating disease, e.g. multiple sclerosis.
Inventor(s):	Hiestand; Peter C. (Austria, CH), Schnell; Christian (Hesingue, FR)
Assignee:	Novartis AG (Basel, CH)
Application Number:	14/257,342
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,187,405

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Novartis	GILENYA	fingolimod	CAPSULE;ORAL	022527-001	Sep 21, 2010		RX	Yes	Yes						TREATMENT OF AUTOIMMUNE DISEASE

Foreign Priority and PCT Information for Patent: 9,187,405

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0612721.1	Jun 27, 2006

Non-Orange Book US Patents Family Members for Patent 9,187,405

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,741,963	S1P receptor modulators for treating multiple sclerosis

International Patents Family Members for US Patent 9,187,405

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2007264031
Australia	2011201844
Australia	2013200356
Australia	2016266058